MARKET WIRE NEWS

Rescheduling Should Send MJ And MSOS Sky High

Source: SeekingAlpha

2025-08-13 12:08:23 ET

American cannabis stocks have surged over the past few days following President Donald Trump’s announcement that he is considering reclassifying marijuana . Currently, marijuana is classified as a Schedule I drug , along with LSD and ecstasy. Go figure, fentanyl is “only” considered a Schedule II drug even though it kills far more people. The Biden administration had considered scheduling marijuana as a Schedule III drug, alongside testosterone and Tylenol with codeine, but ultimately, efforts didn’t advance. Now, it looks like the Trump administration may press ahead and reschedule marijuana as a Schedule III drug. The mere possibility of rescheduling has sent cannabis stocks and ETFs rocking upward, as illustrated below....

Read the full article on Seeking Alpha

For further details see:

Rescheduling Should Send MJ And MSOS Sky High
AdvisorShares Trust Pure US Cannabis

NASDAQ: MSOS

MSOS Trading

-0.39% G/L:

$3.79 Last:

1,514,055 Volume:

$3.77 Open:

mwn-app Ad 300

MSOS Latest News

January 06, 2026 04:15:00 pm
Cannabis Market 2025 Year-End Review

MSOS Stock Data

$802,768,350
197,970,000
N/A
N/A
US

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App